These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 25969547)

  • 41. Direct bioresorbable vascular scaffold implantation: Feasibility and midterm results.
    Suárez de Lezo J; Martín P; Mazuelos F; Nóvoa J; Ojeda S; Pan M; Segura J; Hernández E; Romero M; Melián F; Medina A; Suárez de Lezo J
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):E173-82. PubMed ID: 26268440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100.
    Boeder NF; Dörr O; Bauer T; Mattesini A; Elsässer A; Liebetrau C; Achenbach S; Hamm CW; Nef HM
    Int J Cardiol; 2017 Nov; 246():74-79. PubMed ID: 28579164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up.
    Serruys PW; Ormiston J; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Chevalier B; Smits P; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Wasungu L; Ediebah D; Veldhof S; Onuma Y
    J Am Coll Cardiol; 2016 Feb; 67(7):766-76. PubMed ID: 26892411
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
    Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm.
    Diletti R; Onuma Y; Farooq V; Gomez-Lara J; Brugaletta S; van Geuns RJ; Regar E; de Bruyne B; Dudek D; Thuesen L; Chevalier B; McClean D; Windecker S; Whitbourn R; Smits P; Koolen J; Meredith I; Li D; Veldhof S; Rapoza R; Garcia-Garcia HM; Ormiston JA; Serruys PW
    J Am Coll Cardiol; 2011 Jul; 58(3):258-64. PubMed ID: 21737016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A 12-month angiographic and optical coherence tomography follow-up after bioresorbable vascular scaffold implantation in patients with ST-segment elevation myocardial infarction.
    Kochman J; Tomaniak M; Kołtowski Ł; Jąkała J; Proniewska K; Legutko J; Roleder T; Pietrasik A; Rdzanek A; Kochman W; Brugaletta S; Kaluza GL
    Catheter Cardiovasc Interv; 2015 Oct; 86(4):E180-9. PubMed ID: 26015294
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early and late optical coherence tomography findings following everolimus-eluting bioresorbable vascular scaffold implantation in myocardial infarction: a preliminary report.
    Karanasos A; Muramatsu T; Diletti R; Nauta S; Onuma Y; Lenzen M; Nakatani S; Van Mieghem NM; Schultz C; De Jaegere PP; Serruys PW; Zijlstra F; Regar E; van Geuns RJ
    Hellenic J Cardiol; 2015; 56(2):125-35. PubMed ID: 25854441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Restenosis After Everolimus-eluting Vascular Scaffolding. Angiographic and Optical Coherence Tomography Characterization.
    Chavarría J; Suárez de Lezo J; Ojeda S; Pan M; Segura J; Mazuelos F; Espejo S; López J; Romero M; Suárez de Lezo J
    Rev Esp Cardiol (Engl Ed); 2017 Jul; 70(7):543-550. PubMed ID: 28132761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes.
    Gori T; Schulz E; Hink U; Kress M; Weiers N; Weissner M; Jabs A; Wenzel P; Capodanno D; Münzel T
    JACC Cardiovasc Interv; 2015 May; 8(6):770-777. PubMed ID: 25999097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Very late stent thrombosis after sirolimus-eluting stent implantation: evaluation by intravascular ultrasound and optical coherence tomography.
    Mabuchi T; Fujino S; Yamaguchi M; Noji Y; Ichise T; Aoyama T
    Cardiovasc Interv Ther; 2013 Oct; 28(4):388-93. PubMed ID: 23558923
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA
    J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884
    [TBL] [Abstract][Full Text] [Related]  

  • 52. First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: clinical, Angiographic, and OCT outcomes of CREDIT-1.
    Wang G; Sun Z; Jin Q; Xu K; Li Y; Wang X; Ma Y; Liu H; Zhao X; Wang B; Deng J; Guan S; Ge M; Wang X; Xu B; Han Y
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():744-51. PubMed ID: 25630447
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Everolimus-eluting bioresorbable vascular scaffolds implanted in coronary bifurcation lesions: Impact of polymeric wide struts on side-branch impairment.
    De Paolis M; Felix C; van Ditzhuijzen N; Fam JM; Karanasos A; de Boer S; van Mieghem NM; Daemen J; Costa F; Bergoli LC; Ligthart JM; Regar E; de Jaegere PP; Zijlstra F; van Geuns RJ; Diletti R
    Int J Cardiol; 2016 Oct; 221():656-64. PubMed ID: 27423087
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.
    Ellis SG; Kereiakes DJ; Metzger DC; Caputo RP; Rizik DG; Teirstein PS; Litt MR; Kini A; Kabour A; Marx SO; Popma JJ; McGreevy R; Zhang Z; Simonton C; Stone GW;
    N Engl J Med; 2015 Nov; 373(20):1905-15. PubMed ID: 26457558
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A case report of a recurrent early and late Bioresorbable vascular scaffold thrombosis: serial angiography and optical coherence tomography findings.
    Lee CH; Cho YK; Yoon HJ; Hur SH
    BMC Cardiovasc Disord; 2020 Mar; 20(1):146. PubMed ID: 32204697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Coronary evaginations and peri-scaffold aneurysms following implantation of bioresorbable scaffolds: incidence, outcome, and optical coherence tomography analysis of possible mechanisms.
    Gori T; Jansen T; Weissner M; Foin N; Wenzel P; Schulz E; Cook S; Münzel T
    Eur Heart J; 2016 Jul; 37(26):2040-9. PubMed ID: 26543048
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up.
    Gomez-Lara J; Brugaletta S; Farooq V; van Geuns RJ; De Bruyne B; Windecker S; McClean D; Thuesen L; Dudek D; Koolen J; Whitbourn R; Smits PC; Chevalier B; Morel MA; Dorange C; Veldhof S; Rapoza R; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2011 Jul; 4(7):789-99. PubMed ID: 21777888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial.
    Diletti R; Farooq V; Girasis C; Bourantas C; Onuma Y; Heo JH; Gogas BD; van Geuns RJ; Regar E; de Bruyne B; Dudek D; Thuesen L; Chevalier B; McClean D; Windecker S; Whitbourn RJ; Smits P; Koolen J; Meredith I; Li X; Miquel-Hebert K; Veldhof S; Garcia-Garcia HM; Ormiston JA; Serruys PW
    Heart; 2013 Jan; 99(2):98-105. PubMed ID: 23118346
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study.
    Diletti R; Karanasos A; Muramatsu T; Nakatani S; Van Mieghem NM; Onuma Y; Nauta ST; Ishibashi Y; Lenzen MJ; Ligthart J; Schultz C; Regar E; de Jaegere PP; Serruys PW; Zijlstra F; van Geuns RJ
    Eur Heart J; 2014 Mar; 35(12):777-86. PubMed ID: 24394380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.